ACM
RPRX icon

AlphaCrest Capital Management’s Royalty Pharma RPRX Stock Holding History

AlphaCrest Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-47,943
Closed -$1.93M – 926
2022
Q3 		$1.93M Buy
47,943
+20,924
+77% +$894K 0.12% 246
2022
Q2 		$1.14M Sell
27,019
-33,669
-55% -$1.38M 0.05% 607
2022
Q1 		$2.36M Buy
60,688
+36,495
+151% +$1.43M 0.13% 188
2021
Q4 		$964K Sell
24,193
-60,062
-71% -$2.33M 0.04% 808
2021
Q3 		$3.04M Buy
+84,255
New +$3.27M 0.16% 150

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaCrest Capital Management's RPRX Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Royalty Pharma (RPRX) in Q4 2022, closing a stake of 47,943 shares — an estimated $1.93M sold.

AlphaCrest Capital Management first reported a position in RPRX in Q3 2021 and held it in 5 quarters. The position peaked at $3.04M in Q3 2021. 336 funds tracked by Wall St. Rank hold RPRX as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Royalty Pharma position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 47,943 Royalty Pharma shares in Q4 2022, an estimated $1.93M.
  • AlphaCrest Capital Management first reported a position in Royalty Pharma in Q3 2021 and held it in 5 quarters.
  • AlphaCrest Capital Management's Royalty Pharma position peaked at $3.04M in Q3 2021.
  • 336 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.